Research Report: Policies that encourage biopharmaceutical innovation in middle–income countries
Developed by Charles Rivers Associates; Commissioned by IFPMA
October 2012

The study examined growing biopharmaceutical innovation sectors in Brazil, China, Colombia, India, Malaysia, Russia, South Africa and South Korea, and analyzed key national political and economic factors that foster biopharmaceutical innovation. Eduardo Pisani, IFPMA Director General, said, “In recent years, the number of countries where biopharmaceutical innovation takes places has increased, and this trend is expected to continue. Middle-income countries are becoming increasingly important for innovative activities ranging from early stage research to clinical development. We commissioned this report, because it is crucial for governments and industry to have a clearer understanding of what stimulates and drives innovation in these countries.” The report highlighted the primary success factor as consistent long-term policy and legal frameworks. These should be coupled with effective coordination of national industrial and health policies, encouragement of collaborations between stakeholders, and adequate intellectual property protection. The report further suggests that some countries specialize in those stages of the innovation process in which they have a competitive advantage.

http://www.ifpma.org/fileadmin/content/News/2012/IFPMA_News_Release_CRA_Report_31Oct2012.pdf

CRA Full Report: http://www.ifpma.org/fileadmin/content/Publication/2012/CRA_Policies_that_encourage_innovation_in_middle-income_countries_Web.pdf

CRA Key Findings:
http://www.ifpma.org/fileadmin/content/Publication/2012/CRA_Policies_that_encourage_innovation_in_middle-income_countries_Key_Findings_Web.pdf